WO1991015773A1 - A diagnostic test method - Google Patents
A diagnostic test method Download PDFInfo
- Publication number
- WO1991015773A1 WO1991015773A1 PCT/GB1991/000545 GB9100545W WO9115773A1 WO 1991015773 A1 WO1991015773 A1 WO 1991015773A1 GB 9100545 W GB9100545 W GB 9100545W WO 9115773 A1 WO9115773 A1 WO 9115773A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- sample
- region
- disease
- isoelectric point
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Definitions
- This invention relates to a method of diagnosis for Alzheimer's Disease.
- Alzheimer's Disease is a degenerative brain disorder producing a range of symptoms including dementia. Elevated aluminium levels, virus-like agents and pre ⁇ disposing genetic factors have all been put forward as casual agents. However, the absence of a specific diagnostic test for Alzheimer's Disease has greatly hampered further research and the development of therapeutic agents for the treatment of afflicted individuals.
- This invention exploits the finding that certain polypeptides normally found in blood platelets are present in significantly lowered amounts or are absent from the platelets of Alzheimer's Disease sufferers.
- the invention provides a method of diagnosing Alzheimer's Disease comprising detecting the presence of one or more polypeptides in a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease sufferer, and if such a polypeptide or polypeptides are present, comparing the amount thereof with the amount present in the platelets of disease-free individuals.
- the invention provides a method of diagnosing Alzheimer's Disease comprising separating the components of a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease sufferer, detecting the presence of the separated polypeptides and comparing the amount thereof with the amount of the corresponding polypeptide observed in a corresponding sample taken from a disease-free individual.
- separation techniques can be employed to separate particular polypeptides on the basis of such characteristics as size, solubility, charge and specific binding affinity,n using methods such as dialysis through a semi-permeable membrane; gel- filtration chromatography; ion-exchange chromatography and affinity chromatography (see Stryer L. Biochemistry 2nd Edition, [1981] Pg. 18 to 20, W.H. Freeman and Co. ) .
- the separation of the components may, for example, be • carried out by chromatography or by gel electrophoresis such as polyacrylamide gel electrophoresis (PAGE) .
- PAGE polyacrylamide gel electrophoresis
- two dimensional PAGE is used to separate the polypeptide components in the samples.
- Detection techniques such as immunoassay and colourimetry may be employed in the above methods to determine the presence and/or amount of particular polypeptides in a test sample.
- the invention provides a diagnostic test method for Alzheimer's disease comprising detecting or determining the level of one or more particular polypeptides in a solubilised blood platelet polypeptide sample taken from a test subject, wherein the or each particular polypeptide is one which, if the components of the said sample are subjected to two-dimensional polyacrylamide gel electrophoresis are present in the 110 kDa Mwt region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2.
- the invention further provides a method of diagnosing Alzheimer's Disease comprising separating the components of a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease sufferer by two dimensional PAGE, detecting the presence of the separated polypeptides by staining the gel, and comparing the degree of band staining, in one or more regions selected from the 100 Mwt region at an isoelectric point of approximately 5.4, the 50 kDa Mwt region at an isoelectric point of approximately 5.5, and the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2, with the degree of staining in the corresponding region or regions observed in a sample taken from a disease-free individual.
- the gels are run in pairs, that is one sample from a suspected sufferer with one from a disease-free individual to account for any variability in running conditions.
- the samples taken from suspected sufferers and disease-free individuals are matched as closely as possible for age and sex so that samples are more strictly comparable.
- the presence of the separated polypeptide bands on the gel may be detected using a polypeptide stain such as "Coomassie blue", or by using immunoassay techniques.
- the or each particular polypeptide is extracted from the sample or gel using conventional techniques and is used tc immunise a mammal such as a rabbit in order to raise antisera specific for said polypeptide.
- antisera can be used as an immunoassay reagent in further methods of the invention.
- the invention provides a method for separating from a solubilised blood platelet sample a polypeptide which, if the components of the sample are subjected to two-dimensional polyacrylamide gel electrophoresis, is present in the 110 kDa Mwt
- SUBSTITUTE SHEET region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2 which method comprises: (i) applying said sample to an affinity chromatography column including antibodies specific for said polypeptide, which antibodies are bound to a solid support; (ii) washing the support to remove unbound components of the sample to which the antibodies do not bind specifically; (iii) eluting said polypeptide from the support so that it is obtained in substantially purified form.
- the solid support to which said antibodies bind comprises plastic beads.
- the invention also provides said polypeptide in an isolated and substantially purified form, which polypeptide is present in a reduced concentration in a solubilised blood platelet sample from a sufferer from Alzheimer's disease and which, if the components of such a sample are subjected to two-dimensional polyacrylamide gel electrophoresis are present in the 110 kDa Mwt region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point
- the invention provides an immunoassay method for determining the amount of a particular polypeptide as described previously which method comprises (i) coating a solid support surface with antibodies specific for the particular polypeptide; (ii) washing the support to remove unbound antibodies; (iii) applying a solubilised blood platelet polypeptide sample from a test sample; (iv) washing the support to remove unbound components of the sample; (v) applying labelled antibodies specific for the particular polypeptide; (vi) washing the support to remove any unbound labelled antibodies; (vii) determining the amount of labelled antibody present, which amount is proportional to the amount of the particular polypeptide present in the sample.
- the labelled antibodies are labelled with enzymes (such as peroxidase and phosphatase) which are labelled with enzymes (such as peroxidase and phosphatase) which are labelled with enzymes (such as peroxidase and phosphatase) which are labelled with enzymes (such as peroxidase and phosphatase) which are labelled with enzymes (such as peroxidase and phosphatase) which
- SUBSTITUTESHEET leave a coloured deposit on reaction with substrate.
- the coloured deposit being measurable using colourmetric techniques.
- the invention provides an immunoassay kit for diagnosing Alzheimer's Disease in a solubilised blood platelet polypeptide sample from a test subject comprising
- the above kit further comprises a multiwell plastic plate for using the kit according to the methods of the invention.
- the sample from the test subject is assayed alongside the comparative sample from the disease-free individual so
- examples of the label of the labelled antibodies include an enzyme as mentioned previously, a fluorescent dye which can be seen using ⁇ V microscopy, or a radioactive substance which can be detected by deposition of silver grains from a photographic emulsion or by using counting equipment.
- Fig. 1 shows a diagnostic test according to the inven ion.
- AD Alzheimer's Disease
- CON 5 disease-free control
- Coomassie blue staining was used to detect the presence of the separated polypeptide bands.
- differential staining of certain blood platelet polypeptide bands between Alzheimer's Disease patients and controls provides a specific marker or markers for the diagnosis of the disease in suspected sufferers.
Abstract
The invention provides a method for diagnosing Alzheimer's Disease comprising detecting the amount of one or more polypeptides in a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease sufferer and, if present, comparing the amount thereof with the amount of the polypeptide or polypeptides present in a corresponding sample taken from disease-free individuals. Significantly lowered amounts of said polypeptide or polypeptides in the sample, when compared to the amount in samples from disease-free individuals, being indicative of Alzheimer's Disease.
Description
A DIAGNOSTIC TEST METHOD
This invention relates to a method of diagnosis for Alzheimer's Disease.
Alzheimer's Disease is a degenerative brain disorder producing a range of symptoms including dementia. Elevated aluminium levels, virus-like agents and pre¬ disposing genetic factors have all been put forward as casual agents. However, the absence of a specific diagnostic test for Alzheimer's Disease has greatly hampered further research and the development of therapeutic agents for the treatment of afflicted individuals.
This invention exploits the finding that certain polypeptides normally found in blood platelets are present in significantly lowered amounts or are absent from the platelets of Alzheimer's Disease sufferers.
According to one aspect, the invention provides a method of diagnosing Alzheimer's Disease comprising detecting the presence of one or more polypeptides in a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease sufferer, and if such a polypeptide or polypeptides are present, comparing the amount thereof with the amount present in the platelets of disease-free individuals.
In a further aspect, the invention provides a method of diagnosing Alzheimer's Disease comprising separating the components of a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease sufferer, detecting the presence of the separated polypeptides and comparing the amount thereof with the amount of the corresponding polypeptide observed in a corresponding sample taken from a disease-free individual.
As will be apparent to the skilled worker, many separation techniques can be employed to separate particular polypeptides on the basis of such characteristics as size, solubility, charge and specific binding affinity,n using methods such as dialysis through a semi-permeable membrane; gel- filtration chromatography; ion-exchange chromatography and affinity chromatography (see Stryer L. Biochemistry 2nd Edition, [1981] Pg. 18 to 20, W.H. Freeman and Co. ) .
The separation of the components may, for example, be • carried out by chromatography or by gel electrophoresis such as polyacrylamide gel electrophoresis (PAGE) . Preferably two dimensional PAGE is used to separate the polypeptide components in the samples.
Detection techniques such as immunoassay and colourimetry may be employed in the above methods to determine the presence and/or amount of particular polypeptides in a test sample.
In another aspect the invention provides a diagnostic test method for Alzheimer's disease comprising
detecting or determining the level of one or more particular polypeptides in a solubilised blood platelet polypeptide sample taken from a test subject, wherein the or each particular polypeptide is one which, if the components of the said sample are subjected to two-dimensional polyacrylamide gel electrophoresis are present in the 110 kDa Mwt region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2.
The invention further provides a method of diagnosing Alzheimer's Disease comprising separating the components of a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease sufferer by two dimensional PAGE, detecting the presence of the separated polypeptides by staining the gel, and comparing the degree of band staining, in one or more regions selected from the 100 Mwt region at an isoelectric point of approximately 5.4, the 50 kDa Mwt region at an isoelectric point of approximately 5.5, and the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2, with the degree of staining in the corresponding region or regions observed in a sample taken from a disease-free individual.
SUBSTITUTESHEET
Advantageously, the gels are run in pairs, that is one sample from a suspected sufferer with one from a disease-free individual to account for any variability in running conditions.
Advantageously, the samples taken from suspected sufferers and disease-free individuals are matched as closely as possible for age and sex so that samples are more strictly comparable.
The presence of the separated polypeptide bands on the gel may be detected using a polypeptide stain such as "Coomassie blue", or by using immunoassay techniques.
Preferably, the or each particular polypeptide is extracted from the sample or gel using conventional techniques and is used tc immunise a mammal such as a rabbit in order to raise antisera specific for said polypeptide. Such antisera can be used as an immunoassay reagent in further methods of the invention.
In a further aspect the invention provides a method for separating from a solubilised blood platelet sample a polypeptide which, if the components of the sample are subjected to two-dimensional polyacrylamide gel electrophoresis, is present in the 110 kDa Mwt
SUBSTITUTE SHEET
region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2 which method comprises: (i) applying said sample to an affinity chromatography column including antibodies specific for said polypeptide, which antibodies are bound to a solid support; (ii) washing the support to remove unbound components of the sample to which the antibodies do not bind specifically; (iii) eluting said polypeptide from the support so that it is obtained in substantially purified form.
Preferably the solid support to which said antibodies bind comprises plastic beads.
The invention also provides said polypeptide in an isolated and substantially purified form, which polypeptide is present in a reduced concentration in a solubilised blood platelet sample from a sufferer from Alzheimer's disease and which, if the components of such a sample are subjected to two-dimensional polyacrylamide gel electrophoresis are present in the 110 kDa Mwt region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point
SUBSTITUTE SHEET
of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2.
In a still further aspect the invention provides an immunoassay method for determining the amount of a particular polypeptide as described previously which method comprises (i) coating a solid support surface with antibodies specific for the particular polypeptide; (ii) washing the support to remove unbound antibodies; (iii) applying a solubilised blood platelet polypeptide sample from a test sample; (iv) washing the support to remove unbound components of the sample; (v) applying labelled antibodies specific for the particular polypeptide; (vi) washing the support to remove any unbound labelled antibodies; (vii) determining the amount of labelled antibody present, which amount is proportional to the amount of the particular polypeptide present in the sample.
Preferably the labelled antibodies are labelled with enzymes (such as peroxidase and phosphatase) which
SUBSTITUTESHEET
leave a coloured deposit on reaction with substrate. The coloured deposit being measurable using colourmetric techniques.
In another aspect the invention provides an immunoassay kit for diagnosing Alzheimer's Disease in a solubilised blood platelet polypeptide sample from a test subject comprising
(i) an antibody preparation containing antibodies specific for a particular polypeptide as defined previously;
(ii) An antibody preparation containing labelled antibodies specific for the said polypeptide for determining the amount of said polypeptide in the sample from the test subject; and
(iii) a comparative blood platelet polypeptide sample from an Alzheimer's disease-free individual to allow comparison of the amount of said polypeptide therein with the amount present in the sample from the test subject.
Preferably the above kit further comprises a multiwell plastic plate for using the kit according to the methods of the invention. Advantageously the sample from the test subject is assayed alongside the comparative sample from the disease-free individual so
SUBSTITUTESHEET
that the amount of the particular polypeptide in the respective samples can be readily compared.
As will be apparent to those skilled in the art examples of the label of the labelled antibodies include an enzyme as mentioned previously, a fluorescent dye which can be seen using ϋV microscopy, or a radioactive substance which can be detected by deposition of silver grains from a photographic emulsion or by using counting equipment.
A preferred embodiment of the invention will now be described by way of example only, with reference to Fig. 1.
Fig. 1 shows a diagnostic test according to the inven ion.
A total of 13 2-D SDS PAGE were carried out to separate the components of solubilised platelet polypeptide samples.
Eight Alzheimer's Disease (ALZ) patients and 5 disease-free control (CON) individuals were tested. These were matched as closely as possible for age (63 * 4 years for ALZ group and 62 * 5 years for CON group) and sex (4 males/4 females for ALZ group and 3 males/2
SUBSTITUTESHEET
females for CON group).
Gels were run in paris, that is, one ALZ with one CON, to account for the variability in running conditions.
Coomassie blue staining was used to detect the presence of the separated polypeptide bands.
In 5 out of 8 SDS-gels from the ALZ group, there was a consistent decrease in the degree of Coomassie blue staining of a spot around the 110 kDa Mwt region with an isoelectric point of approximately 5.4, as shown in Fig. 1, B=ALZ, marked 1. However, all 5 ΞDS-gels from the control group showed a mich stronger staining as shown in Fig. 1, A=CON, marked 1.
Further differential staining was observed in the spot around the 50 kDa Mwt region with an isoelectric point of approximately 5.5, marked 2 in Fig. 1 and the spot marked 3 around the 40 kDa Mwt region with an isoelectric point in the range 5.6 to 6.2.
Thus, the differential staining of certain blood platelet polypeptide bands between Alzheimer's Disease patients and controls provides a specific marker or markers for the diagnosis of the disease in suspected sufferers.
SUBSTITUTESHEET
Claims
1. A diagnostic test method for Alzheimer's Disease characterised in that at least one polypeptide of a solubilised blood platelet polypeptide sample taken from a suspected Alzheimer's Disease suffer is detected and, if present, the amount thereof is compared with the amount of the same polypeptide in a corresponding sample taken from a disease-free individual .
2. A diagnostic test method for Alzheimer's disease comprising detecting or determining the level of one or more particular polypeptides in a solubilised blood platelet polypeptide sample taken from a test subject, wherein the or each particular polypeptide is one which, if the components of the said sample are subjected to two-dimensional polyacrylamide gel electrophoresis are present in the 110 kDa Mwt region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2.
3. A method as claimed in claim 1 wherein the components of the solubilised blood platelet polypeptide sample are separated prior to the
SUBSTITUTESHEET detection of the polypeptide.
4. A method as claimed in claim 3 wherein the separation of the components is achieved by two dimensional polyacrylamide gel electrophoresis.
5. A method as claimed in claim 2 wherein the presence of the separated polypeptides in the gel is detected by staining the gel and comparing the degree of band staining in one or more regions selected from the 110 kDa Mwt region at an isoelectric point of 5.4, the 50 kDa Mwt region at an isoelectric point of 5.5 and the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2, with the degree of staining in the corresponding region or regions in a corresponding sample taken from a disease-free i dividual .
6. A method for separating from a solubilised blood platelet sample a polypeptide which, if the components of the sample are subjected to two-dimensional polyacrylamide gel electrophoresis are present in the 110 kDa Mwt region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2 which method comprises:
SUBSTITUTESHEET (i) applying said sample to an affinity chromatography column including antibodies specific for said polypeptide, which antibodies are bound to a solid support;
(ii) washing the support to remove unbound components of the sample to which the antibodies do not bind specifically;
(iii) eluting said polypeptide from the support so that it is obtained in substantially purified form.
7. A polypeptide in isolated and purified form, which polypeptide is present in a reduced concentration in a solubilised blood platelet sample from a sufferer from Alzheimer's disease and which, if the components of such a sample are subjected to two-dimensional polyacrylamide gel electrophoresis are present in the 110 kDa Mwt region at an isoelectric point of 5.4 and/or the 50 kDa Mwt region at an isoelectric point of 5.5 and/or the 40 kDa Mwt region at an isoelectric point in the range of from 5.6 to 6.2.
8. A method as claimed in claim 1 wherein the particular polypeptide or polypeptides are detected by immunoassay.
9. An immunoassay method for determining the amount
SUBSTITUTESHEET of a particular polypeptide as claimed in claim 1 or 2 comprises: (i) coating a solid support surface with antibodies specific for the particular polypeptide; (ii) washing the support to remove unbound antibodies; (iii) applying a solubilised blood platelet polypeptide sample from a test sample; (iv) washing the support to remove unbound components of the sample; (v) applying labelled antibodies specific for the particular polypeptide; (vi) washing the support to remove any unbound labelled antibodies; (vii) determining the amount cf labelled antibody- present, which amount is proportional to the amount of the particular polypeptide present in the sample.
10. An immunoassay kit for diagnosing Alzheimer's disease in a solubilised blood platelet polypeptide sample from a test subject comprises: (i) an antibody preparation containing antibodies specific for a particular polypeptide as defined in claim 1 or 2; (ii) An antibody preparation containing labelled
SUBSTITUTESHEET antibodies specific for the said polypeptide for determining the amount of said polypeptide in the sample from the test subject; and (iii) a comparative blood platelet polypeptide sample from an Alzheimer's disease-free individual to allow comparison of the amount of said polypeptide therein with the amount present in the sample from the test subject.
SUBSTITUTESHEET
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9007922.9 | 1990-04-07 | ||
GB909007922A GB9007922D0 (en) | 1990-04-07 | 1990-04-07 | A diagnostic test method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991015773A1 true WO1991015773A1 (en) | 1991-10-17 |
Family
ID=10674077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1991/000545 WO1991015773A1 (en) | 1990-04-07 | 1991-04-08 | A diagnostic test method |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU7677991A (en) |
GB (1) | GB9007922D0 (en) |
WO (1) | WO1991015773A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025911A1 (en) * | 1992-06-17 | 1993-12-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosing alzheimer's disease and schizophrenia |
WO1997013152A1 (en) * | 1995-09-29 | 1997-04-10 | Yeda Research And Development Co., Ltd. | Assay for the diagnosis of dementia |
US5714471A (en) * | 1995-01-06 | 1998-02-03 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5863902A (en) * | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
US7166202B2 (en) * | 2001-07-16 | 2007-01-23 | Protein Forest, Inc. | Matrixes, arrays, systems and methods |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272055A (en) * | 1991-12-24 | 1993-12-21 | The University Of Kentucky Research Foundation | Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
WO1989007657A1 (en) * | 1988-02-10 | 1989-08-24 | The Children's Medical Center Corporation | Amyloid protein precursors, genetic probes, antibodies, and methods of use |
-
1990
- 1990-04-07 GB GB909007922A patent/GB9007922D0/en active Pending
-
1991
- 1991-04-08 AU AU76779/91A patent/AU7677991A/en not_active Abandoned
- 1991-04-08 WO PCT/GB1991/000545 patent/WO1991015773A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
WO1989007657A1 (en) * | 1988-02-10 | 1989-08-24 | The Children's Medical Center Corporation | Amyloid protein precursors, genetic probes, antibodies, and methods of use |
Non-Patent Citations (4)
Title |
---|
Biotechnology, volume 7, February 1989, C.R. Abraham et al.: "Alzheimer's disease: Recent advances in understanding the brain amyloid deposits", pages 147-152 * |
Science, volume 248, no. 4956, May 1990, W.E. Van Nostrand et al.: "Protease nexin-II (amyloidb-protein precursor): A platelet x-granule protein", pages 745-748 * |
Science, volume 248, no. 4959, 1 June 1990, R.P. Smith et al.: "Platelet coagulation factor XIa-inhibitor, a form of Alzheimer myloid precursor protein" * |
The Journal of Biological Chemistry, volume 265, no. 26, 15 September 1990, The American Society for Biochemistry and Molecular Biologoy, Inc., (US), A.I. Bush et al.: "The amyloid precursor protein of Alzheimer's disease is released by human platelets", pages 15977-15983 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025911A1 (en) * | 1992-06-17 | 1993-12-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosing alzheimer's disease and schizophrenia |
US5962419A (en) * | 1995-01-06 | 1999-10-05 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5714471A (en) * | 1995-01-06 | 1998-02-03 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5863902A (en) * | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
US5872101A (en) * | 1995-01-06 | 1999-02-16 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
US5969100A (en) * | 1995-01-06 | 1999-10-19 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
US6015879A (en) * | 1995-01-06 | 2000-01-18 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US6017887A (en) * | 1995-01-06 | 2000-01-25 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
US6051684A (en) * | 1995-01-06 | 2000-04-18 | Sibia Neurosciences Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
US6153171A (en) * | 1995-01-06 | 2000-11-28 | Sibia Neurosciences, Inc. | Methods for identifying compounds effective for treating neurodegenerative disorders and for monitoring the therapeutic intervention therefor |
WO1997013152A1 (en) * | 1995-09-29 | 1997-04-10 | Yeda Research And Development Co., Ltd. | Assay for the diagnosis of dementia |
US7166202B2 (en) * | 2001-07-16 | 2007-01-23 | Protein Forest, Inc. | Matrixes, arrays, systems and methods |
US7914656B2 (en) | 2001-07-16 | 2011-03-29 | Protein Forest, Inc. | Matrixes, arrays, systems and methods |
Also Published As
Publication number | Publication date |
---|---|
AU7677991A (en) | 1991-10-30 |
GB9007922D0 (en) | 1990-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Edwards et al. | Proteins of human urine. III. Identification and two-dimensional electrophoretic map positions of some major urinary proteins. | |
Manni et al. | The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency | |
CA1181685A (en) | Method for the identification and purification of human lung tumor-associated antigens (hltaa) and clinical detection and determination of these antigens | |
Krøll et al. | DNA-binding proteins in Yoshida ascites tumor fluid | |
AU773265B2 (en) | S100 proteins and autoantibodies as serum markers for cancer | |
US4626355A (en) | Method of determining alcohol consumption | |
US5246835A (en) | Method of diagnosing renal diseases | |
EP0535162B1 (en) | Analyte variant analysis | |
AU740707B2 (en) | Diagnosis of colorectal cancer and proteins and antibodies for use therein | |
WO1991015773A1 (en) | A diagnostic test method | |
EP0856158B1 (en) | Assay for the diagnosis of dementia | |
Dermer et al. | Enhancement techniques for detecting trace and fluid-specific components in two-dimensional electrophoresis patterns. | |
CA2665707C (en) | Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum | |
WO1998035229A1 (en) | Diagnosis of disease using tears | |
WO2004019045A2 (en) | Method for the diagnosis of alzheimer disease | |
Parsons et al. | Purification and Identification of a Human‐Serum DNA‐Binding Protein Associated with Malignant Diseases | |
Nakajima et al. | Emergence of low‐mobility t lymphocytes in cancer patients and its clinical significance | |
Fukal et al. | Chromatographic separation of papain evaluated by immunochemical methods | |
GB2174807A (en) | Quantitative screening assay of tumor globulin from gastric juices | |
Robinson et al. | Studies on inherited variants of blood proteins. I. Two dimensional electrophoretic analysis of chromatographic fractions of serum proteins | |
CA1049405A (en) | Test method to determine pulmonary embolism | |
Barthe et al. | Isolation of the" cystic fibrosis protein" from serum. | |
JP2595921B2 (en) | Assay method for anti-RNA binding protein antibody | |
Rassam et al. | Affinity separation and partial characterization of serologically active Leishmania donovani antigens | |
CA2025231A1 (en) | Cancer marker and monoclonal antibodies specific therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA HU JP KR SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |